2022-03-21 - Cancer Synoptic Reporting Project Group Meeting

1

Cancer modeling changes

@Scott Campbell @Nicola Ingram

Review editorial changes for primary and metastatic cancer disorders.  See links in action section

2

Lung cancer focality

@Scott Campbell

1. Focal, non-focal (multiple)

2. Local metastases - sidedness? 

3. count of local metastases

3

Treatment effect

@Scott Campbell

Continue discussion:

What are we measuring when assessing "treatment effect"?  

Is this a histologic change?  Viability of tumor cells?

1. Primary site

2. Lymph node

Note: SSA wonders about property in this model

1. Primary site

   Open

   

   
   
   
   

2. Lymph node

Open

Will review model.  This observable pertains to the process of regression/change in the neoplasm after antineoplastic therapy.  So, observable could be modeled as presence of process changes.

Still a discussion.  What is being measured?  (Degree of presence of tumor). Can this be reproduced...base question is tumor there or not s/p therapy...tumor gone is best...everything else is questionable for the patient

4

Patterns

@Scott Campbell

1. How to handle patterns within histologies

   1. Lung (Lepidic, acinar)

   2. DCIS

   3. Bladder (differentiation)

We can use the morphologic descriptors...maybe...TBD

5

AJCC update?

@Jim Case

Any updates that can be shared?

@Jim Case meeting with AJCC on Wednesday 26-Jan to continue/finalize contract issues